Compare DexCom, Inc. (DXCM) vs TeraWulf Inc (WULF) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

WULF trades at $17.92, down 7.68% in the past 24 hours, with a bearish technical signal and support near $17. The stock shows weak fundamentals with a net loss of $661.42 million in 2025 and negative profit margins, but holds a 100% buy rating from analysts. Recent news highlights a major 20-year, $19 billion AI infrastructure deal with Anthropic, positioning the company in the high-demand data center space.

The outlook is polarized: strong analyst optimism with a $36 consensus price target reflects growth potential from AI partnerships, but high execution risks, negative earnings, and cash burn pose significant challenges. Investors face substantial upside if AI contracts materialize successfully, alongside volatility from operational losses and sector headwinds.